Original Title: Behandling med intravenøs immunoglobulin ved PANS/PANDAS-tilstandene hos barn

Authors' objectives: To investigate the effect and safety of treatment with immunoglobulins in the conditions Pediatric Acute onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infection (PANDAS).

Authors' results and conclusions: RESULTS: Our findings are the following: No conlusion can be drawn on whether intravenous immunoglobulin has any effect on health-related quality of life as no study has reported data on this outcome. It is uncertain whether intravenous immunoglobulin improves level of functioning or symptoms (very low certainty of evidence, GRADE ⊕◯◯◯). Side-effects and adverse events can occur in line with the summary of product characteristics (low certainty of evidence GRADE ⊕⊕◯◯). Costs related to immunoglobulin treatment will vary considerably depending on dose and weight. As none of the human immunoglobulin preparations on the market have approved indication with specified dosage for the treatment of PANS/PANDAS, it is difficult to estimate what the costs will be if immunoglobulin treatment is introduced into the Norwegian clinical practice.

Project Status: Completed

Year Published: 2021

URL for published report: https://www.fhi.no/en/publ/2021/Intravenous-immunoglobulin-treatment-in-children-with-PANS-PANDAS-conditions/

English language abstract: An English language summary is available

Publication Type: Rapid Review

Country: Norway

Organisation Name: Norwegian Institute of Public Health

Contact Address: P.O. Box 222 Skoyen, N-0123, Oslo